{"id":179,"date":"2022-08-09T11:40:33","date_gmt":"2022-08-09T11:40:33","guid":{"rendered":"https:\/\/countrylanding-dev-001.azurewebsites.net\/au\/?page_id=179"},"modified":"2025-06-24T00:34:02","modified_gmt":"2025-06-24T00:34:02","slug":"home","status":"publish","type":"page","link":"https:\/\/www.biomarin.com\/en-au\/","title":{"rendered":"Home"},"content":{"rendered":"
\n
<\/div>\n\t
<\/div>\n \t
<\/div>\n\t
\n\t\t
\n\t\t\t
\n\t\t\t \t\t\t\t\t\t\t\t\t\t\t\t

Seeking to make a difference in rare disease\n<\/h1>\n\t\t\t\t\t\t\t\t\t\t\t\t

At BioMarin, we view ourselves as a team of pioneers, willing to take risks in the quest to \ufb01nd new solutions to address serious, debilitating challenges in rare diseases, and motivated by the desire to help improve the lives of patients with unmet medical needs.<\/p>\n\t\t\t\t\t\t\t\t\n

\n \t\t\t\t About BioMarin Australia<\/a>\t\t\t\t <\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n

\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t

Our therapy areas\n<\/h2>\n \t\t\t\t\n
\n
\n
\n
\n \"A <\/div>\n <\/figure>\n <\/div>\n
\n

Achondroplasia\n<\/h3>\n

Achondroplasia is a rare genetic bone growth disorder and the most common form of disproportionate short stature. It is caused by a change in the fibroblast growth factor receptor 3 (FGFR3) gene, which impairs the growth of bone in the cartilage of the growth plate.<\/p>\n

Read more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n
\n
\n \"Image <\/div>\n <\/figure>\n <\/div>\n
\n

Phenylketonuria (PKU)\n<\/h3>\n

Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH).<\/p>\n

Read more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n
\n
\n \"Image <\/div>\n <\/figure>\n <\/div>\n
\n

Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease\n<\/h3>\n

Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease is an ultra-rare and rapidly progressive paediatric brain disorder and one of the most common forms of neuronal ceroid lipofuscinosis, a group of inherited disorders collectively known as Batten disease.<\/p>\n

Read more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n
\n
\n \"Image <\/div>\n <\/figure>\n <\/div>\n
\n

Mucopolysaccharidosis VI (MPS VI)\n<\/h3>\n

Mucopolysaccharidosis VI (MPS VI), also known as Maroteaux-Lamy Syndrome, is an ultra-rare inherited lysosomal storage disorder caused by the deficiency of N-acetylgalactosamine-4-sulfatase (arylsulfatase B), an enzyme required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs).<\/p>\n

Read more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n
\n
\n \"Image <\/div>\n <\/figure>\n <\/div>\n
\n

Mucopolysaccharidosis type IVA (MPS IVA)\n<\/h3>\n

Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome, is an ultra-rare inherited lysosomal storage disorder caused by the deficiency of N-acetylgalactosamine-6-sulfatase (GALNS), an enzyme required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs).<\/p>\n

Read more<\/a><\/p>\n <\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n\t
\n\t\t
\n\t\t
\n

Scientific discovery driven by genetic diversity<\/h2>\n

BioMarin is committed to translating genetic discoveries into transformative medicines. Our approach focuses on diseases with precisely understood mechanisms that are rooted in GENETICS<\/strong>, developing TARGETED <\/b>therapeutic interventions that address the underlying causes of diseases, utilising the readily ACCESSIBLE <\/b>endpoints that are proximal to the disease pathway, and enabling TRANSFORMATIONAL <\/b>changes to the way patients feel, function, and survive.<\/p>\n

Read more about our science on BioMarin.com<\/a><\/p>\n <\/div>\n \n

\n \n \n \n \n
\n
\n \"Image <\/div>\n <\/figure>\n <\/div>\n \t\t<\/div>\n\t<\/div>\n<\/div>\n\n
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t \t\t\t\t

Products available in Australia\n<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\t

Please select a product to access further information including the Consumer Medicine Information and Product Information.<\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t

\n\t\t\t \n
\n
\n

BRINEURA\u00ae<\/sup> (cerliponase alfa)<\/sub>\n<\/h4>\n \n

BRINEURA\u00ae<\/sup> is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.<\/p>\n \n <\/div>\n

\n \n

Find out more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

KUVAN\u00ae<\/sup> (sapropterin dihydrochloride)<\/sub>\n<\/h4>\n \n

KUVAN\u00ae<\/sup> is indicated for the treatment of hyperphenylalaninemia (HPA) by reducing blood phenylalanine levels in patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.<\/p>\n \n <\/div>\n

\n \n

Find out more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

NAGLAZYME\u00ae<\/sup> (galsulfase (rch))<\/sub>\n<\/h4>\n \n

NAGLAZYME\u00ae<\/sup> is indicated for the treatment of Mucopolysaccharidosis VI (MPS VI) storage disorder, a disease in which the enzyme level of Nacetylgalactosamine 4-sulfatase is absent or lower than normal.<\/p>\n \n <\/div>\n

\n \n

Find out more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

PALYNZIQ\u00ae<\/sup> (pegvaliase)<\/sub>\n<\/h4>\n \n

PALYNZIQ\u00ae<\/sup> is indicated for the treatment of patients with phenylketonuria (PKU) aged 16 and older, whose blood phenylalanine levels cannot be adequately controlled by other means such as by diet.<\/p>\n \n <\/div>\n

\n \n

Find out more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

VIMIZIM\u00ae<\/sup> (elosulfase alfa (rch))<\/sub>\n<\/h4>\n \n

VIMIZIM\u00ae<\/sup> is indicated for the treatment of MPS IVA \u00a0(Mucopolysaccharidosis Type IVA, Morquio A Syndrome).<\/p>\n \n <\/div>\n

\n \n

Find out more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

VOXZOGO\u00ae<\/sup> (vosoritide)<\/sub>\n<\/h4>\n \n

VOXZOGO\u00ae<\/sup> is indicated for the treatment of achondroplasia in paediatric patients whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.<\/p>\n \n <\/div>\n

\n \n

Find out more<\/a><\/p>\n <\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n
\n\t\t
\n\t\t\t
\n\t\t\t\t
<\/div>\n\t\t\t\t
\n\t\t\t\t \t\t\t\t\t
\n
\n\t\t\t\t\t \t\t\t\t\t \t\t\t\t\t\t

We seek the big effect\n<\/h2>\n\t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t

Strategically focusing on rare diseases with defined genetic defects, BioMarin strives to develop innovative therapies that are first- or best-in-class.<\/p>\n\t\t\t\t\t\t \t\t\t\t\t <\/div>\n\t\t\t\t\t

\n

View our product pipeline on BioMarin.com<\/a><\/p>\n <\/div>\n\t\t\t\t\t <\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n\t
\n\t\t
\n\t\t\t
\n\t\t\t \t\t\t\t

Treatment is only the beginning\n<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t
\n\t\t\t \n
\n \t \n\n \"Image \n\t
\n

Patient organisations\n<\/h4>\n \n

For each disease state we seek to treat, there are several organisations and resources that provide great insight and support services.<\/p>\n \n <\/div>\n

\n \n

Find out more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n \t \n\n \"scientist \n\t
\n

Grants and donations\n<\/h4>\n \n

We provide a variety of opportunities to further support patient communities.<\/p>\n \n <\/div>\n

\n \n

Find out more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n \t \n\n \"Scientist \n\t
\n

Independent research (For healthcare professionals only)\n<\/h4>\n \n

We provide product and funding support for independent research in rare diseases and genetic disorders to unleash scientific innovation and meet the unmet medical needs.<\/p>\n \n <\/div>\n

\n \n

Find out more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n \t \n\n \"test \n\t
\n

Data request (For healthcare professionals only)\n<\/h4>\n \n

We seek to improve patient care and drive advancement in medical science, through providing qualified scientific researchers access to de-identified patient-level data collected in clinical trials.<\/p>\n \n <\/div>\n

\n \n

Find out more<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n \t \n\n \"dropping \n\t
\n

Independent medical education (For healthcare professionals only)\n<\/h4>\n \n

We offer funding to support accredited or non-accredited medical education activities for HCPs regarding BioMarin-controlled or -influenced content.<\/p>\n \n <\/div>\n

\n \n

Find out more<\/a><\/p>\n <\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n\t
\n\t\t
\n\t\t
\n \n \n \n \n
\n
\n \"Image <\/div>\n <\/figure>\n <\/div>\n \n
\n

There\u2019s something special about BioMarin<\/h2>\n

Hope. It’s where BioMarin’s story begins. It’s what we work to deliver every day. As a biopharmaceutical company, our success stems from our unwavering focus on science and the hope our therapies can bring to patients and their families. Explore our story, and let our opportunities speak to you.<\/p>\n

View career information at BioMarin.com<\/a><\/p>\n <\/div>\n \t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n\t
\n\t\t
\n\t\t
\n \n \n \n \n
\n
\n \"Image <\/div>\n <\/figure>\n <\/div>\n \n
\n

Keep track of our latest investor and media information<\/h2>\n

Transparency creates trust. As a listed biopharmaceutical company, BioMarin is obligated to enhance transparency of our operation with readily available information. BioMarin enables you to keep abreast of our latest development and events, track the NASDAQ index, and get access to other company-related useful information. You will be impressed by how much we have devoted to achieving corporate responsibility, with the aim of boosting efficiency and reducing the environmental impacts.<\/p>\n

Find out more at BioMarin.com<\/a><\/p>\n

Read our latest press releases<\/a><\/p>\n <\/div>\n \t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n\t
\n\t\t
\n\t\t\t
\n\t\t\t \t\t\t\t

BioMarin contact details\n<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t
\n\t\t\t \n
\n
\n

Registered Office\n<\/h4>\n \n

BioMarin Pharmaceutical Australia Pty Ltd<\/strong>
\n119 Willoughby Rd, Crows Nest, NSW 2065, Australia<\/p>\n

Email:<\/strong>\u00a0anz@bmrn.com<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

Place an Order\n<\/h4>\n \n

Registered pharmacies and hospitals only:
\nPatients and consumers should speak to their community pharmacy or prescriber for more information.<\/em><\/p>\n

Australia<\/strong>
\nDHL Direct to Market
\nToll Free: 1800 077 421<\/a> (Option 1)
\nEmail:\u00a0d2mcs@dhl.com<\/a><\/p>\n

New Zealand<\/strong>
\nHealthcare Logistics
\nPh: 09 969 0734<\/a>
\nE-mail: orders@healthcarelogistics.co.nz<\/a><\/p>\n \n <\/div>\n

\n \n

Australia DHL D2M iStore<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

Medical Information\n<\/h4>\n \n

Hours: 24 hrs\/day, 7 days\/week
\nEmail: Medinfo@bmrn.com<\/a><\/p>\n

Australia<\/strong>
\nToll Free: 1800 387 876<\/a>
\nLocal: 02 8520 3255<\/a><\/p>\n

New Zealand<\/strong>
\nToll Free: 0800 882 012<\/a>
\nLocal: 09 801 1051<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

Adverse Events\n<\/h4>\n \n

Hours: 24 hrs\/day, 7 days\/week
\nEmail: Medinfo@bmrn.com<\/a>
\nSubmit an Adverse Event \u203a<\/a><\/p>\n

Australia<\/strong>
\nToll Free: 1800 387 876<\/a>
\nLocal: 02 8520 3255<\/a><\/p>\n

New Zealand<\/strong>
\nToll free: 0800 882 012<\/a>
\nLocal: 09 801 1051<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

Report a Product Complaint\/Enquiry\n<\/h4>\n \n

Registered pharmacies and hospitals only:<\/p>\n

Australia<\/strong>
\nDHL Direct to Market
\nToll Free: 1800 077 421<\/a> (Option 3)
\nEmail:\u00a0d2mcs@dhl.com<\/a><\/p>\n

New Zealand<\/strong>
\nHealthcare Logistics
\nPh: 09 969 0734<\/a>
\nEmail: orders@healthcarelogistics.co.nz<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

Clinical Trial Information\n<\/h4>\n \n

For healthcare professionals only:<\/p>\n

Email:<\/strong> Medinfo@bmrn.com<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

Media Relations\n<\/h4>\n \n

Email:<\/strong> anz@bmrn.com<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n
\n

Investor Relations\n<\/h4>\n \n

Email:<\/strong> ir@bmrn.com<\/a>
\nTel:<\/strong> +1 (415) 455-7558<\/a><\/p>\n \n <\/div>\n

\n \n

View investor information at BioMarin.com<\/a><\/p>\n <\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque ullamcorper, neque vel mollis eleifend, ante urna congue elit, mattis hendrerit ipsum justo at libero.<\/p>\n","protected":false},"author":9,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-179","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nBioMarin Pharmaceutical Australia: Advancing Rare Disease Therapies<\/title>\n<meta name=\"description\" content=\"BioMarin Pharmaceutical Australia is a leader in developing and commercialising innovative biopharmaceuticals for rare diseases driven by genetic causes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biomarin.com\/en-au\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioMarin Pharmaceutical Australia: Advancing Rare Disease Therapies\" \/>\n<meta property=\"og:description\" content=\"BioMarin Pharmaceutical Australia is a leader in developing and commercialising innovative biopharmaceuticals for rare diseases driven by genetic causes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biomarin.com\/en-au\/\" \/>\n<meta property=\"og:site_name\" content=\"BioMarin Australia\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/BioMarinOfficial\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T00:34:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biomarin.com\/en-au\/wp-content\/uploads\/sites\/2\/2022\/01\/biomarin-logo.jpeg?v=0.49\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biomarin.com\/en-au\/\",\"url\":\"https:\/\/www.biomarin.com\/en-au\/\",\"name\":\"BioMarin Pharmaceutical Australia: Advancing Rare Disease Therapies\",\"isPartOf\":{\"@id\":\"https:\/\/www.biomarin.com\/en-au\/#website\"},\"datePublished\":\"2022-08-09T11:40:33+00:00\",\"dateModified\":\"2025-06-24T00:34:02+00:00\",\"description\":\"BioMarin Pharmaceutical Australia is a leader in developing and commercialising innovative biopharmaceuticals for rare diseases driven by genetic causes.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biomarin.com\/en-au\/#breadcrumb\"},\"inLanguage\":\"en-AU\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biomarin.com\/en-au\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biomarin.com\/en-au\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biomarin.com\/en-au\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Home\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biomarin.com\/en-au\/#website\",\"url\":\"https:\/\/www.biomarin.com\/en-au\/\",\"name\":\"BioMarin Australia\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.biomarin.com\/en-au\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biomarin.com\/en-au\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-AU\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biomarin.com\/en-au\/#organization\",\"name\":\"BioMarin Australia\",\"url\":\"https:\/\/www.biomarin.com\/en-au\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-AU\",\"@id\":\"https:\/\/www.biomarin.com\/en-au\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biomarin.com\/en-au\/wp-content\/uploads\/sites\/2\/2022\/01\/biomarin-logo.jpeg\",\"contentUrl\":\"https:\/\/www.biomarin.com\/en-au\/wp-content\/uploads\/sites\/2\/2022\/01\/biomarin-logo.jpeg\",\"width\":800,\"height\":800,\"caption\":\"BioMarin Australia\"},\"image\":{\"@id\":\"https:\/\/www.biomarin.com\/en-au\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/BioMarinOfficial\/\",\"https:\/\/www.linkedin.com\/company\/biomarin\/\",\"https:\/\/www.youtube.com\/channel\/UCsJU_aj8_xNFso8ZkfShRJQ\/featured\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioMarin Pharmaceutical Australia: Advancing Rare Disease Therapies","description":"BioMarin Pharmaceutical Australia is a leader in developing and commercialising innovative biopharmaceuticals for rare diseases driven by genetic causes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biomarin.com\/en-au\/","og_locale":"en_US","og_type":"article","og_title":"BioMarin Pharmaceutical Australia: Advancing Rare Disease Therapies","og_description":"BioMarin Pharmaceutical Australia is a leader in developing and commercialising innovative biopharmaceuticals for rare diseases driven by genetic causes.","og_url":"https:\/\/www.biomarin.com\/en-au\/","og_site_name":"BioMarin Australia","article_publisher":"https:\/\/www.facebook.com\/BioMarinOfficial\/","article_modified_time":"2025-06-24T00:34:02+00:00","og_image":[{"width":800,"height":800,"url":"https:\/\/www.biomarin.com\/en-au\/wp-content\/uploads\/sites\/2\/2022\/01\/biomarin-logo.jpeg?v=0.49","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biomarin.com\/en-au\/","url":"https:\/\/www.biomarin.com\/en-au\/","name":"BioMarin Pharmaceutical Australia: Advancing Rare Disease Therapies","isPartOf":{"@id":"https:\/\/www.biomarin.com\/en-au\/#website"},"datePublished":"2022-08-09T11:40:33+00:00","dateModified":"2025-06-24T00:34:02+00:00","description":"BioMarin Pharmaceutical Australia is a leader in developing and commercialising innovative biopharmaceuticals for rare diseases driven by genetic causes.","breadcrumb":{"@id":"https:\/\/www.biomarin.com\/en-au\/#breadcrumb"},"inLanguage":"en-AU","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biomarin.com\/en-au\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.biomarin.com\/en-au\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biomarin.com\/en-au\/"},{"@type":"ListItem","position":2,"name":"Home"}]},{"@type":"WebSite","@id":"https:\/\/www.biomarin.com\/en-au\/#website","url":"https:\/\/www.biomarin.com\/en-au\/","name":"BioMarin Australia","description":"","publisher":{"@id":"https:\/\/www.biomarin.com\/en-au\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biomarin.com\/en-au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-AU"},{"@type":"Organization","@id":"https:\/\/www.biomarin.com\/en-au\/#organization","name":"BioMarin Australia","url":"https:\/\/www.biomarin.com\/en-au\/","logo":{"@type":"ImageObject","inLanguage":"en-AU","@id":"https:\/\/www.biomarin.com\/en-au\/#\/schema\/logo\/image\/","url":"https:\/\/www.biomarin.com\/en-au\/wp-content\/uploads\/sites\/2\/2022\/01\/biomarin-logo.jpeg","contentUrl":"https:\/\/www.biomarin.com\/en-au\/wp-content\/uploads\/sites\/2\/2022\/01\/biomarin-logo.jpeg","width":800,"height":800,"caption":"BioMarin Australia"},"image":{"@id":"https:\/\/www.biomarin.com\/en-au\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/BioMarinOfficial\/","https:\/\/www.linkedin.com\/company\/biomarin\/","https:\/\/www.youtube.com\/channel\/UCsJU_aj8_xNFso8ZkfShRJQ\/featured"]}]}},"_links":{"self":[{"href":"https:\/\/www.biomarin.com\/en-au\/wp-json\/wp\/v2\/pages\/179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biomarin.com\/en-au\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biomarin.com\/en-au\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biomarin.com\/en-au\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biomarin.com\/en-au\/wp-json\/wp\/v2\/comments?post=179"}],"version-history":[{"count":255,"href":"https:\/\/www.biomarin.com\/en-au\/wp-json\/wp\/v2\/pages\/179\/revisions"}],"predecessor-version":[{"id":10963,"href":"https:\/\/www.biomarin.com\/en-au\/wp-json\/wp\/v2\/pages\/179\/revisions\/10963"}],"wp:attachment":[{"href":"https:\/\/www.biomarin.com\/en-au\/wp-json\/wp\/v2\/media?parent=179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}